---
title: "enGene Holdings Inc. (ENGN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ENGN.US.md"
symbol: "ENGN.US"
name: "enGene Holdings Inc."
industry: "Biotechnology"
---

# enGene Holdings Inc. (ENGN.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.engene.com](https://www.engene.com) |

## Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of n...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.52 | 384/603 | - | - | - |
| PB | 3.86 | 264/603 | 2.67 | 1.09 | 0.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-05T05:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 64% |
| Overweight | 3 | 27% |
| Hold | 1 | 9% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.08 |
| Highest Target | 33.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ENGN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ENGN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ENGN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.